Compare CNS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNS | IMNM |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | 2004 | 2020 |
| Metric | CNS | IMNM |
|---|---|---|
| Price | $67.51 | $21.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $72.50 | $32.10 |
| AVG Volume (30 Days) | 251.9K | ★ 1.0M |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | ★ 14.23 | 7.06 |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $427,536,000.00 | $9,041,000.00 |
| Revenue This Year | $7.83 | N/A |
| Revenue Next Year | $11.02 | $11.53 |
| P/E Ratio | $29.40 | ★ N/A |
| Revenue Growth | ★ 4.07 | N/A |
| 52 Week Low | $58.39 | $5.15 |
| 52 Week High | $88.49 | $27.65 |
| Indicator | CNS | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 59.09 | 43.67 |
| Support Level | $63.76 | $18.98 |
| Resistance Level | $68.30 | $22.57 |
| Average True Range (ATR) | 2.06 | 1.18 |
| MACD | 0.30 | -0.31 |
| Stochastic Oscillator | 83.73 | 15.51 |
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.